TWIST BIOSCIENCE CORP (TWST) Fundamental Analysis & Valuation

NASDAQ:TWST • US90184D1000

Current stock price

62.61 USD
+0.73 (+1.18%)
At close:
62 USD
-0.61 (-0.97%)
After Hours:

This TWST fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. TWST Profitability Analysis

1.1 Basic Checks

  • TWST had negative earnings in the past year.
  • TWST had a negative operating cash flow in the past year.
  • In the past 5 years TWST always reported negative net income.
  • In the past 5 years TWST always reported negative operating cash flow.
TWST Yearly Net Income VS EBIT VS OCF VS FCFTWST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M

1.2 Ratios

  • TWST has a Return On Assets of -12.00%. This is amongst the best in the industry. TWST outperforms 80.23% of its industry peers.
  • Looking at the Return On Equity, with a value of -16.79%, TWST belongs to the top of the industry, outperforming 83.14% of the companies in the same industry.
Industry RankSector Rank
ROA -12%
ROE -16.79%
ROIC N/A
ROA(3y)-24.14%
ROA(5y)-23.35%
ROE(3y)-31.13%
ROE(5y)-29.44%
ROIC(3y)N/A
ROIC(5y)N/A
TWST Yearly ROA, ROE, ROICTWST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 -60

1.3 Margins

  • The Gross Margin of TWST (51.62%) is better than 75.39% of its industry peers.
  • TWST's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for TWST so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 51.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.04%
GM growth 5Y9.75%
TWST Yearly Profit, Operating, Gross MarginsTWST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. TWST Health Analysis

2.1 Basic Checks

  • TWST does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for TWST has been increased compared to 1 year ago.
  • TWST has more shares outstanding than it did 5 years ago.
  • TWST has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TWST Yearly Shares OutstandingTWST Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
TWST Yearly Total Debt VS Total AssetsTWST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • TWST has an Altman-Z score of 9.88. This indicates that TWST is financially healthy and has little risk of bankruptcy at the moment.
  • TWST's Altman-Z score of 9.88 is amongst the best of the industry. TWST outperforms 80.81% of its industry peers.
  • There is no outstanding debt for TWST. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 9.88
ROIC/WACCN/A
WACC9.53%
TWST Yearly LT Debt VS Equity VS FCFTWST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 3.78 indicates that TWST has no problem at all paying its short term obligations.
  • TWST has a Current ratio (3.78) which is comparable to the rest of the industry.
  • TWST has a Quick Ratio of 3.37. This indicates that TWST is financially healthy and has no problem in meeting its short term obligations.
  • TWST's Quick ratio of 3.37 is in line compared to the rest of the industry. TWST outperforms 43.60% of its industry peers.
Industry RankSector Rank
Current Ratio 3.78
Quick Ratio 3.37
TWST Yearly Current Assets VS Current LiabilitesTWST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. TWST Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 38.46% over the past year.
  • Looking at the last year, TWST shows a quite strong growth in Revenue. The Revenue has grown by 18.59% in the last year.
  • Measured over the past years, TWST shows a very strong growth in Revenue. The Revenue has been growing by 33.11% on average per year.
EPS 1Y (TTM)38.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.66%
Revenue 1Y (TTM)18.59%
Revenue growth 3Y22.75%
Revenue growth 5Y33.11%
Sales Q2Q%16.89%

3.2 Future

  • Based on estimates for the next years, TWST will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.58% on average per year.
  • TWST is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.32% yearly.
EPS Next Y12.68%
EPS Next 2Y16.95%
EPS Next 3Y17.58%
EPS Next 5YN/A
Revenue Next Year17.17%
Revenue Next 2Y16.12%
Revenue Next 3Y15.91%
Revenue Next 5Y15.32%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
TWST Yearly Revenue VS EstimatesTWST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
TWST Yearly EPS VS EstimatesTWST Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -1 -2 -3 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. TWST Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TWST. In the last year negative earnings were reported.
  • Also next year TWST is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TWST Price Earnings VS Forward Price EarningsTWST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TWST Per share dataTWST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • TWST's earnings are expected to grow with 17.58% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.95%
EPS Next 3Y17.58%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TWST Dividend Analysis

5.1 Amount

  • TWST does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TWST Fundamentals: All Metrics, Ratios and Statistics

TWIST BIOSCIENCE CORP

NASDAQ:TWST (4/21/2026, 4:57:06 PM)

After market: 62 -0.61 (-0.97%)

62.61

+0.73 (+1.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-02
Earnings (Next)04-30
Inst Owners122.59%
Inst Owner Change-0.06%
Ins Owners1.47%
Ins Owner Change6.97%
Market Cap3.84B
Revenue(TTM)391.56M
Net Income(TTM)-76.58M
Analysts84.71
Price Target51.61 (-17.57%)
Short Float %23.42%
Short Ratio11.09
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-8.39%
Min EPS beat(2)-14%
Max EPS beat(2)-2.79%
EPS beat(4)1
Avg EPS beat(4)-2.91%
Min EPS beat(4)-14%
Max EPS beat(4)17.53%
EPS beat(8)4
Avg EPS beat(8)-7.26%
EPS beat(12)8
Avg EPS beat(12)0.24%
EPS beat(16)12
Avg EPS beat(16)6.24%
Revenue beat(2)1
Avg Revenue beat(2)0.3%
Min Revenue beat(2)-0.26%
Max Revenue beat(2)0.85%
Revenue beat(4)1
Avg Revenue beat(4)-0.51%
Min Revenue beat(4)-1.51%
Max Revenue beat(4)0.85%
Revenue beat(8)5
Avg Revenue beat(8)0.83%
Revenue beat(12)9
Avg Revenue beat(12)1.76%
Revenue beat(16)11
Avg Revenue beat(16)1.82%
PT rev (1m)0%
PT rev (3m)28.1%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-11.07%
EPS NY rev (1m)-0.21%
EPS NY rev (3m)-19.78%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.72%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.91%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.8
P/FCF N/A
P/OCF N/A
P/B 8.42
P/tB 10.64
EV/EBITDA N/A
EPS(TTM)-2.08
EYN/A
EPS(NY)-1.33
Fwd EYN/A
FCF(TTM)-1.41
FCFYN/A
OCF(TTM)-0.83
OCFYN/A
SpS6.39
BVpS7.44
TBVpS5.88
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -12%
ROE -16.79%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 51.62%
FCFM N/A
ROA(3y)-24.14%
ROA(5y)-23.35%
ROE(3y)-31.13%
ROE(5y)-29.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.04%
GM growth 5Y9.75%
F-Score5
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 144.77%
Cap/Sales 9.12%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.78
Quick Ratio 3.37
Altman-Z 9.88
F-Score5
WACC9.53%
ROIC/WACCN/A
Cap/Depr(3y)74.54%
Cap/Depr(5y)223.62%
Cap/Sales(3y)6.8%
Cap/Sales(5y)18.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.66%
EPS Next Y12.68%
EPS Next 2Y16.95%
EPS Next 3Y17.58%
EPS Next 5YN/A
Revenue 1Y (TTM)18.59%
Revenue growth 3Y22.75%
Revenue growth 5Y33.11%
Sales Q2Q%16.89%
Revenue Next Year17.17%
Revenue Next 2Y16.12%
Revenue Next 3Y15.91%
Revenue Next 5Y15.32%
EBIT growth 1Y17.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year70.31%
EBIT Next 3Y29.55%
EBIT Next 5Y23.24%
FCF growth 1Y32.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y54.2%
OCF growth 3YN/A
OCF growth 5YN/A

TWIST BIOSCIENCE CORP / TWST Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for TWIST BIOSCIENCE CORP?

ChartMill assigns a fundamental rating of 4 / 10 to TWST.


Can you provide the valuation status for TWIST BIOSCIENCE CORP?

ChartMill assigns a valuation rating of 0 / 10 to TWIST BIOSCIENCE CORP (TWST). This can be considered as Overvalued.


Can you provide the profitability details for TWIST BIOSCIENCE CORP?

TWIST BIOSCIENCE CORP (TWST) has a profitability rating of 3 / 10.